News Background

Oxford, UK – 13 September 2016. OGT, The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The CytoCell® ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC). The new additions complement OGT’s existing NSCLC probe range (including ALK Breakapart, EGFR Amplification and EML Breakapart), providing a comprehensive solution for diagnosis and patient stratification.

Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death in males. Worldwide, lung cancer accounted for 1.8 million new cases in 2012,1 with NSCLC accounting for 85% of these.2 Manisha Maurya, Clinical Scientist, Royal Marsden NHS Foundation Trust, explained the significance of the new CytoCell probes: “As NSCLC can be classified into different molecular subtypes, accurate genomic identification of the correct subtype is of paramount importance for targeted treatment. In our validation studies, the new CytoCell probes for NCSLC showed tight, bright signals allowing easy visualisation and scoring of results. These probes will further improve our ability to stratify and treat NSCLC.”

Senior Product Manager for Pathology at OGT, Steve Chatters also commented: “Cancer research is advancing at a rapid rate. At OGT, we work with leading clinical scientists to develop innovative products that utilise the latest scientific understanding. This is exemplified by our new CytoCell ROS1 Plus Breakapart Probe, which has been designed to cover not only the ROS1 region but also the region deleted in ROS1-GOPC fusions, enabling more comprehensive analysis.”

The probes are available in two economical sizes and are premixed in hybridisation buffer — saving time and minimising potential errors. Fully optimised for use on formalin-fixed, paraffin-embedded (FFPE) samples, CytoCell FISH probes deliver high-intensity signals with minimal background for accurate, reliable results and confident diagnoses. 

 

References

  1. Ervik M, et al (2016) Cancer Today. Lyon, France: International Agency for Research on Cancer. Cancer Today. Available from: http://gco.iarc.fr/today, accessed 30/08/2016
  2. Molina JR, et al (2008) Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic proceedings Mayo Clinic. 83(5):584-594

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

You might also be interested in

OGT's CytoCell portfolio available via Sysmex in China and Spain Listing Image

OGT's CytoCell portfolio available via Sysmex in China and Spain

06 Jul 2020

Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.

Read
OGT celebrates opening of new Cambridge site Listing Image

OGT celebrates opening of new Cambridge site

06 Jun 2019

State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.

Read
FDA grants de novo designation for OGT’s AML/MDS FISH probes Listing Image

FDA grants de novo designation for OGT’s AML/MDS FISH probes

30 Jan 2019

Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter